1364 related articles for article (PubMed ID: 25403646)
1. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Packer M; McMurray JJ; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile M; Andersen K; Arango JL; Arnold JM; Bělohlávek J; Böhm M; Boytsov S; Burgess LJ; Cabrera W; Calvo C; Chen CH; Dukat A; Duarte YC; Erglis A; Fu M; Gomez E; Gonzàlez-Medina A; Hagège AA; Huang J; Katova T; Kiatchoosakun S; Kim KS; Kozan Ö; Llamas EB; Martinez F; Merkely B; Mendoza I; Mosterd A; Negrusz-Kawecka M; Peuhkurinen K; Ramires FJ; Refsgaard J; Rosenthal A; Senni M; Sibulo AS; Silva-Cardoso J; Squire IB; Starling RC; Teerlink JR; Vanhaecke J; Vinereanu D; Wong RC;
Circulation; 2015 Jan; 131(1):54-61. PubMed ID: 25403646
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR;
N Engl J Med; 2014 Sep; 371(11):993-1004. PubMed ID: 25176015
[TBL] [Abstract][Full Text] [Related]
3. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
4. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
Desai AS; Solomon S; Claggett B; McMurray JJ; Rouleau J; Swedberg K; Zile M; Lefkowitz M; Shi V; Packer M
Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296397
[TBL] [Abstract][Full Text] [Related]
5. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
7. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
[TBL] [Abstract][Full Text] [Related]
8. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
9. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
Circulation; 2016 Jun; 133(23):2254-62. PubMed ID: 27143684
[TBL] [Abstract][Full Text] [Related]
10. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
Desai AS; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Chen F; Gong J; Rizkala AR; Brahimi A; Claggett B; Finn PV; Hartley LH; Liu J; Lefkowitz M; Shi V; Zile MR; Solomon SD
Eur Heart J; 2015 Aug; 36(30):1990-7. PubMed ID: 26022006
[TBL] [Abstract][Full Text] [Related]
11. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.
Kristensen SL; Preiss D; Jhund PS; Squire I; Cardoso JS; Merkely B; Martinez F; Starling RC; Desai AS; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR; McMurray JJ; Packer M;
Circ Heart Fail; 2016 Jan; 9(1):. PubMed ID: 26754626
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
Ehteshami-Afshar S; Mooney L; Dewan P; Desai AS; Lang NN; Lefkowitz MP; Petrie MC; Rizkala AR; Rouleau JL; Solomon SD; Swedberg K; Shi VC; Zile MR; Packer M; McMurray JJV; Jhund PS; Hawkins NM
J Am Heart Assoc; 2021 Feb; 10(4):e019238. PubMed ID: 33522249
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
[TBL] [Abstract][Full Text] [Related]
14. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
[TBL] [Abstract][Full Text] [Related]
15. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
16. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
[TBL] [Abstract][Full Text] [Related]
17. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
18. Health-Related Quality of Life Outcomes in PARADIGM-HF.
Lewis EF; Claggett BL; McMurray JJV; Packer M; Lefkowitz MP; Rouleau JL; Liu J; Shi VC; Zile MR; Desai AS; Solomon SD; Swedberg K
Circ Heart Fail; 2017 Aug; 10(8):. PubMed ID: 28784687
[TBL] [Abstract][Full Text] [Related]
19. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
Balmforth C; Simpson J; Shen L; Jhund PS; Lefkowitz M; Rizkala AR; Rouleau JL; Shi V; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
JACC Heart Fail; 2019 Jun; 7(6):457-465. PubMed ID: 31078482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]